VIC Clinical Trials
Navigation
Year Filter
2005→2025
From
To
Source: ClinicalTrials.gov
API v2 · n = 7,019 trials
Data as of Apr 2026
VICTORIA, AUSTRALIA
Victoria Clinical Trials Network
Victoria, Australia · Clinical Trials Intelligence

Victoria Clinical Trials Market

Exhaustive analysis of 7,019 registered trials — market size, therapeutic areas, sponsors, geography, equity, and opportunity.

7,019
Total Trials
1,991
Active
1,051
Recruiting
Total Registered Trials
7,019
All statuses, all time
Currently Active
1,991
Recruiting + Active
Now Recruiting
1,051
Open to enrolment
Completed
3,847
Reached primary endpoint
Trials per 100k Pop.
102
Victorian population
Unique Trial Sites
2,759
Facilities in Victoria
Terminated Trials
844
12.0% of total
Active per 100k Pop.
29.3
Current activity rate

Trial Status Breakdown

All registered trials

  • Completed
  • Recruiting
  • Terminated
  • Active (Not Recruiting)
  • Unknown
  • Not Yet Recruiting

Study Type

Interventional vs Observational

  • Interventional
  • Observational
  • Expanded access

Sponsor Type

Industry vs Academic/Government

01,5003,0004,5006,000IndustryAcademic /Gov
Market Context
Population
6.88M
ABS ERP June 2024
Trials / 100k
102
All-time registered
Results Posted
39.3%
Of all trials
Multi-site Trials
36.5%
Of all trials
Trial counts sourced from ClinicalTrials.gov API v2 using AREA[LocationState]"Victoria" filter. Population: ABS ERP June 2024 (6,881,600). Data retrieved April 2026.n=7,019 · as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
02

Status & Pipeline

Current trial status distribution and recruitment pipeline

Status Distribution

All registered trials (all-time)

  • Completed
  • Recruiting
  • Terminated
  • Active (Not Recruiting)
  • Unknown
  • Not Yet Recruiting
  • Withdrawn
  • By Invitation
  • APPROVED_FOR_MARKETING
  • Suspended
  • NO_LONGER_AVAILABLE
  • AVAILABLE

Status Count

Sorted by volume

01,0002,0003,0004,000RecruitingActive (NotRecruiting)Not Yet RecruitingBy InvitationSuspendedAVAILABLE

Status Detail

Counts and percentages

StatusCount% of TotalShare
Completed
3,84754.8%
Recruiting
1,05115.0%
Terminated
84412.0%
Active (Not Recruiting)
82111.7%
Unknown
2573.7%
Not Yet Recruiting
821.2%
Withdrawn
540.8%
By Invitation
370.5%
APPROVED_FOR_MARKETING
90.1%
Suspended
80.1%
NO_LONGER_AVAILABLE
70.1%
AVAILABLE
20.0%

Recruitment Activity by Year

Trials by outcome status per start year (2005–2025)

200520062007200820092010201120122013201420152016201720182019202020212022202320242025090180270360
  • Recruiting
  • Completed
  • Terminated
Status breakdown is all-time (not filtered by year range). Recruitment trend chart respects the year filter.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
03

Phase Distribution

Clinical trial phase breakdown and evolution over time

Phase Distribution

All trials with phase data (all-time)

  • Phase III
  • Phase II
  • Phase I
  • Phase I/II
  • Phase IV
  • Phase II/III
  • Early Phase I

Phase Volume

Sorted by count

07001,4002,1002,800Phase IIIPhase IIPhase IPhase I/IIPhase IVPhase II/IIIEarly Phase I

Phase Detail

PhaseCount% of TotalShare
Phase III
2,71938.7%
Phase II
1,40720.0%
Phase I
88612.6%
Phase I/II
3995.7%
Phase IV
2914.1%
Phase II/III
1842.6%
Early Phase I
240.3%

Phase Mix by Year

Stacked phase distribution per start year (2005–2025)

2005200620072008200920102011201220132014201520162017201820192020202120222023202420250100200300400
  • Phase I
  • Phase I/II
  • Phase II
  • Phase II/III
  • Phase III
  • Phase IV
Phase classification as reported by sponsors in ClinicalTrials.gov. Phase N/A includes observational studies.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
04

Therapeutic Areas

Click any bar or row to explore sponsors, phases, sites, and conditions for that TA

↗ Click any bar, pie segment, or table row to open the drill-down panel for that therapeutic area.

Therapeutic Area Distribution

All registered trials (all-time) — click to drill down

  • Oncology
  • Other
  • Cardiovascular
  • Infectious Disease
  • Immunology & Rheumatology
  • Neurology
  • Respiratory
  • Endocrinology & Metabolism
  • Renal & Urology
  • Mental Health
  • Ophthalmology
  • Dermatology
  • Musculoskeletal
  • Paediatrics
  • Haematology
  • Gastroenterology
  • Women's Health

Top Therapeutic Areas

By trial volume — click a bar to drill down

07001,4002,1002,800OncologyOtherCardiovascularInfectiousDiseaseImmunology &RheumatologyNeurologyRespiratoryEndocrinology &MetabolismRenal & UrologyMental Health

Therapeutic Area Detail

Click any row to open the drill-down panel

Therapeutic AreaTrials% ShareRelative Volume
Oncology
2,61937.3%
↗ drill-down
Other
88012.5%
↗ drill-down
Cardiovascular
6959.9%
↗ drill-down
Infectious Disease
5537.9%
↗ drill-down
Immunology & Rheumatology
5087.2%
Neurology
4546.5%
↗ drill-down
Respiratory
2914.1%
↗ drill-down
Endocrinology & Metabolism
2874.1%
Renal & Urology
1271.8%
Mental Health
1191.7%
Ophthalmology
1031.5%
↗ drill-down
Dermatology
961.4%
↗ drill-down
Musculoskeletal
741.1%
↗ drill-down
Paediatrics
741.1%
↗ drill-down
Haematology
640.9%
↗ drill-down
Gastroenterology
600.9%
Women's Health
150.2%

Top Therapeutic Areas by Year

Trial registrations for top 6 TAs (2005–2025)

2005200620072008200920102011201220132014201520162017201820192020202120222023202420250100200300400
  • Oncology
  • Other
  • Cardiovascular
  • Infectious Disease
  • Immunology & Rheumatology
  • Neurology
Therapeutic area classification derived algorithmically from MeSH condition terms and intervention keywords. Click any bar or row to explore per-TA detail.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
05

Sponsors & Funders

Who is funding and running clinical trials in Victoria

Industry
5,469
77.9% of all trials
Academic / Gov
1,550
22.1% of all trials

Sponsor Class Distribution

By organisation type

  • Industry
  • Other
  • Government
  • Network
  • NIH
  • Federal

Sponsor Class by Year

Industry vs other sponsors (2005–2025)

200520072009201120132015201720192021202320250150300450600
  • Industry
  • Other
  • NIH
  • Government
  • Network

Top 20 Sponsors

By number of registered trials in Victoria

085170255340Novartis PharmaceuticalsBristol-Myers SquibbAbbVieEli Lilly and CompanyBoehringer IngelheimGilead SciencesBayerPeter MacCallum CancerCentr…SanofiNovo Nordisk A/S

Sponsor Class Detail

ClassTrials% ShareVolume
Industry
5,46977.9%
Other
1,10815.8%
Government
2012.9%
Network
1792.6%
NIH
610.9%
Federal
10.0%
Lead sponsor only. Sponsor class as reported in ClinicalTrials.gov. Collaborators and co-funders are not reflected.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
06

Geography

Trial site density heatmap, health service regions, suburbs, and facilities

Trial Site Density Map

Victoria — trial activity by suburb and key facility locations

28 suburbs · colour = trial density
Low density
Medium density
High density

Trials by Health Service Region

Absolute count and per 100k population

03,0006,0009,00012,000Melbourne MetroBarwon SouthWestGrampiansHumeLoddon MalleeGippsland
060120180240Melbourne MetroBarwon SouthWestGrampiansHumeLoddon MalleeGippsland

Health Service Region Detail

RegionTrialsPopulationPer 100kType
Melbourne Metro
10,7634,800,000224.2Metro
Barwon South West
396340,000116.5Regional
Grampians
138240,00057.5Regional
Hume
132310,00042.6Regional
Loddon Mallee
91330,00027.6Regional
Gippsland
31280,00011.1Regional

Top 20 Suburbs by Trial Count

Victorian suburbs with most trial activity

MelbourneParkvilleClaytonHeidelbergBox HillFitzroyEast MelbourneGeelongFrankstonMalvernCarltonFootscrayPrahranRichmondSt AlbansBallaratCamberwellEppingWodongaBendigo0900180027003600

Top 20 Trial Sites / Facilities

By number of registered trials

0150300450600GSK Investigational SitePeter MacCallum CancerCentreResearch SiteMonash Medical CentreAlfred HospitalRoyal Children's HospitalMonash HealthThe Royal MelbourneHospitalAlfred HealthNucleus Network
Suburb/city from LocationCity field. Region classification uses ABS GCCSA boundaries. Facility coordinates geocoded from suburb names.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
07

Metro vs Regional Equity

Geographic equity in clinical trial access across Victoria

⚠
Metro trials are 327% more concentrated per capita than regional Victoria
Metro: 224.2 trials/100k pop. · Regional: 52.5 trials/100k pop.
Melbourne Metro
10,763
Trials
224.2
Per 100k
76.2%
of VIC pop.
Regional Victoria
788
Trials
52.5
Per 100k
23.8%
of VIC pop.

Trial Count

Metro vs Regional

Melbourne MetroRegional Victoria03,0006,0009,00012,000

Trials per 100k Population

Normalised for population size

Melbourne MetroRegional Victoria060120180240

Equity Insights

  • • Melbourne Metro hosts 93.2% of trials but only 76.2% of Victoria's population.
  • • Regional Victoria (25% of population) accounts for 6.8% of trials — a significant access gap.
  • • Geelong, Ballarat, and Bendigo are the strongest regional trial centres but remain far below metro density.
  • • Opportunity: expanding trial sites to regional health services could improve patient access and recruitment diversity.
Metro vs regional classification based on ABS GCCSA. Per-capita figures use ABS ERP June 2024 sub-state population estimates.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
08

State Benchmarks

Victoria compared to other Australian states and global clinical trial hubs

VIC Rank (Australia)
#3
by trials per 100k pop.
VIC Trials / 100k
102
all-time registered
Global Rank
#8
vs major trial hubs

Australian State Comparison

Total registered trials — sorted by volume (AREA[LocationState] filter, ClinicalTrials.gov)

02,0004,0006,655VictoriaNew SouthWalesQueenslandSouth AustraliaWesternAustraliaTasmaniaACTNorthernTerritory6,2555,6963,7002,8662,71546942060

Note: Victoria leads NSW in absolute trial count (6,255 vs 5,696) despite a smaller population — reflecting Melbourne's concentration of academic medical centres and research hospitals.

Trials per 100k Population

Population-normalised — sorted by rate (ABS ERP June 2024)

04590173South AustraliaWesternAustraliaVictoriaACTTasmaniaNew SouthWalesQueenslandNorthernTerritory153.092.990.988.982.167.967.823.9

SA leads on per-capita rate (153.0) due to SAHMRI and RAH concentration relative to its smaller population. Victoria ranks 3rd nationally at 90.9 per 100k.

Australian State Detail

StateTrialsPopulationPer 100kRank
South Australia
2,8661.9M153.0#1
Western Australia
2,7152.9M92.9#2
VictoriaVIC
6,2556.9M90.9#3
Australian Capital Territory
4200.5M88.9#4
Tasmania
4690.6M82.1#5
New South Wales
5,6968.4M67.9#6
Queensland
3,7005.5M67.8#7
Northern Territory
600.3M23.9#8

Global Benchmark Comparison

Victoria vs major clinical trial jurisdictions — sorted by rate (trials per 100k population)

04590135180SwitzerlandSouth Australia(AU)USA (avg)WesternAustralia (AU)Canada (avg)Japan (avg)Queensland (AU)

* Global figures are approximate estimates based on ClinicalTrials.gov registrations. Dashed line = Victoria benchmark.

State counts use AREA[LocationState] filter for consistent cross-state comparison. Population: ABS ERP June 2024. Global benchmarks are approximate estimates.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
09

Top Conditions

Most frequently studied medical conditions in Victorian clinical trials

Top 25 Conditions

By number of trials

03570105140Breast CancerMelanomaNon-Small Cell Lung CancerDiabetes Mellitus, Type 2Rheumatoid ArthritisCrohn's DiseaseAtopic DermatitisColorectal CancerHIV InfectionsChronic LymphocyticLeukemiaHealthy VolunteersCystic FibrosisCoronary Artery Disease

Top 25 Conditions — Detail Table

#ConditionTrials% of Total
01Breast Cancer1361.9%
02Multiple Myeloma891.3%
03Melanoma771.1%
04Heart Failure701.0%
05Non-Small Cell Lung Cancer681.0%
06Ulcerative Colitis660.9%
07Diabetes Mellitus, Type 2650.9%
08Prostate Cancer630.9%
09Rheumatoid Arthritis610.9%
10Alzheimer's Disease600.9%
11Crohn's Disease600.9%
12Obesity560.8%
13Atopic Dermatitis500.7%
14Advanced Solid Tumors500.7%
15Colorectal Cancer490.7%
16Cancer490.7%
17HIV Infections480.7%
18Advanced Solid Tumor460.7%
19Chronic Lymphocytic Leukemia460.7%
20Ovarian Cancer440.6%
21Healthy Volunteers440.6%
22Asthma440.6%
23Cystic Fibrosis440.6%
24Non-small Cell Lung Cancer440.6%
25Coronary Artery Disease430.6%
Condition names as reported by sponsors in ClinicalTrials.gov. One trial may list multiple conditions; each is counted separately.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
10

Enrollment

Trial size distribution, participant demographics, and site characteristics

Median Enrollment
234
participants
Mean Enrollment
955
participants
Total Enrolled
4.4M
across all trials
Avg Sites / Trial
1.56
global locations

Enrollment Size Buckets

Trials by participant count

1-5051-200501-10005000+0500100015002000

Gender Eligibility

Participant gender criteria

04,0008,000All GendersFemale OnlyMale Only

Healthy Volunteers

Acceptance criteria

04,0008,000
Multi-site Trials
2,565
36.5% of all trials
Single-site Trials
3,396
63.5% of all trials
International Trials
5,600
Multi-country studies
Results Posted
39.3%
2,760 trials
Enrollment figures are target/estimated values as reported by sponsors. Actual enrollment may differ significantly.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
11

Trial Design

Allocation, masking, intervention types, and study models

Allocation

Randomisation method

  • Randomised
  • NA
  • Non-Randomised

Masking

Blinding approach

08501,7002,5503,400NONEQUADRUPLEDOUBLETRIPLESINGLE

Responsible Party

Who manages the trial

04,0008,000SPONSORPRINCIPALINVESTIGATORSPONSORINVESTIGATOR

Intervention Types

Top 10 by frequency

01,5003,0004,5006,000DRUGBIOLOGICALOTHERDEVICEPROCEDURERADIATIONBEHAVIORALDIAGNOSTICTESTCOMBINATIONPRODUCTDIETARYSUPPLEMENT

Intervention Models

Study design model

01,5003,0004,5006,000PARALLELSINGLE GROUPSEQUENTIALCROSSOVERFACTORIAL
Trial design attributes (allocation, masking, intervention type, study model) as reported by sponsors in ClinicalTrials.gov.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
12

International Collaboration

Countries co-hosting trials with Victoria and global trial network

International Trials
5,600
Multi-country studies
Multi-site Trials
2,565
36.5% of all trials
Avg Sites / Trial
1.56
Global locations

Top 20 Co-hosting Countries

Countries appearing alongside Victoria in multi-site trials

01,5003,0004,5006,000CanadaGermanyFrancePolandSouth KoreaCzechiaTaiwanHungaryArgentinaAustria

Country Collaboration Detail

#CountryShared Trials% of VIC Trials
01United States4,58465.3%
02Canada3,41748.7%
03Spain3,21845.8%
04Germany3,06043.6%
05United Kingdom3,03743.3%
06France2,92241.6%
07Italy2,85740.7%
08Poland2,27632.4%
09Belgium2,16530.8%
10South Korea2,00228.5%
11Netherlands1,84526.3%
12Czechia1,61323.0%
13Israel1,56022.2%
14Taiwan1,54422.0%
15Japan1,53421.9%
16Hungary1,48021.1%
17Brazil1,47921.1%
18Argentina1,43320.4%
19New Zealand1,41220.1%
20Austria1,35719.3%
International collaboration defined as trials with sites in Australia AND at least one other country. Country data from LocationCountry field.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
13

Termination & Results

Why trials stop early and how often results are published

Total Terminated
844
12% of all trials
Results Posted
39.3%
2,760 trials
Completed w/ Results
2,105
of 3,847 completed

Termination Reasons

Why trials stopped early

  • Sponsor/Funding
  • Other
  • Efficacy/Futility
  • Poor Enrolment
  • Safety Concerns
  • Not Specified
  • Protocol Issues
  • COVID-19

Results Availability

All registered trials

  • Results Posted
  • No Results

Completed Trials

Results publication rate

  • Completed + Results
  • Completed, No Results

Termination Reasons Detail

ReasonCount% of TerminatedShare
Sponsor/Funding
23928.3%
Other
19322.9%
Efficacy/Futility
11814.0%
Poor Enrolment
11113.2%
Safety Concerns
9210.9%
Not Specified
839.8%
Protocol Issues
50.6%
COVID-19
30.4%

Termination Rate by Year

Terminated trials as a proportion of all trials started (2010–2025)

2010201120122013201420152016201720182019202020212022202320242025020406080
Termination reasons from the WhyStopped free-text field. Categories derived by keyword clustering. Results publication from HasResults field.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
14

Opportunity Analysis

Where trial activity aligns with or diverges from disease burden — identifying market gaps

Under-represented
10 TAs
Trial activity below disease burden — opportunity to expand
CardiovascularRespiratoryEndocrinology & MetabolismRenal & UrologyMental HealthMusculoskeletalPaediatricsHaematologyGastroenterologyWomen's Health
Aligned
0 TAs
Trial activity proportional to disease burden
Over-represented
4 TAs
Trial activity exceeds disease burden — strong research focus
OncologyOtherInfectious DiseaseImmunology & Rheumatology

Opportunity Ratio by Therapeutic Area

Ratio of trial activity to disease burden (1.0 = perfectly aligned; <0.7 = under-represented; >1.5 = over-represented)

036912Women's HealthMental HealthHaematologyPaediatricsCardiovascularNeurologyDermatologyOncologyOther
Under-represented (<0.7)Aligned (0.7–1.5)Over-represented (>1.5)

Trial Activity vs Disease Burden

Each dot = a therapeutic area. Points above the diagonal = over-represented; below = under-represented.

05101520Disease Burden %010203040Trial Activity %

Full Opportunity Analysis Table

All therapeutic areas with trial vs burden comparison

Therapeutic AreaTrialsTrial %Burden %RatioStatus
Women's Health
150.2%2.5%0.08Under-represented
Musculoskeletal
741.1%9.8%0.11Under-represented
Mental Health
1191.7%13%0.13Under-represented
Gastroenterology
600.9%4.2%0.21Under-represented
Haematology
640.9%2.8%0.32Under-represented
Renal & Urology
1271.8%3.5%0.51Under-represented
Paediatrics
741.1%2%0.55Under-represented
Respiratory
2914.1%7.2%0.57Under-represented
Cardiovascular
6959.9%17.2%0.58Under-represented
Endocrinology & Metabolism
2874.1%6.8%0.60Under-represented
Neurology
4546.5%8.5%0.76Balanced
Ophthalmology
1031.5%1.8%0.83Balanced
Dermatology
961.4%1.5%0.93Balanced
Infectious Disease
5537.9%5.5%1.44Over-represented
Oncology
2,61937.3%19.5%1.91Over-represented
Immunology & Rheumatology
5087.2%3.2%2.25Over-represented
Other
88012.5%1.3%9.62Over-represented
Opportunity ratio = disease burden (DALYs) per Victorian trial. Higher ratio = relatively underserved condition. Disease burden from AIHW/GBD 2021.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026
15

Trial Intelligence

Searchable database of recently recruiting Victorian trials and sponsor directory

Showing 500 of 500 recently recruiting trials (2022–2025)
NCT IDTitleStatusPhaseTASponsorSiteN
NCT07107945A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease RecruitingIIIRenal & UrologyBoehringer IngelheimClayton120
NCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphoActive (Not Recruiting)IIIOncologyNational Cancer Institute (NCI)Parkville244
NCT06351631A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingIIIRespiratoryMerck Sharp & Dohme LLCClayton400
NCT06151574Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer WRecruitingIIIOncologyBoehringer IngelheimHeidelberg416
NCT04606446Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingIIOncologyPfizerMelbourne320
NCT06424288A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureRecruitingIIICardiovascularBoehringer IngelheimFrankston6,000
NCT07116967Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RecruitingIIIImmunology & RheumatologyBristol-Myers SquibbCarlton3,040
NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CRecruitingIIIInfectious DiseaseBoehringer IngelheimClayton1,590
NCT07136012OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major CardioRecruitingIIICardiovascularAmgenClayton11,000
NCT07064473EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes,RecruitingIIICardiovascularBoehringer IngelheimClayton11,800
NCT07221149A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in CombinatioRecruitingII/IIIOncologyBristol-Myers SquibbClayton690
NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus TrRecruitingIIIOncologyMerck Sharp & Dohme LLCFrankston1,200
NCT06371417Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)RecruitingIImmunology & RheumatologyChugai PharmaceuticalMelbourne144
NCT05927571A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in ParticRecruitingIOncologyGenentech, Inc.Melbourne120
NCT05091424A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab aRecruitingIOncologyHoffmann-La RocheEast Melbourne137
NCT06926660A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseaseActive (Not Recruiting)IIRenal & UrologyBoehringer IngelheimHeidelberg416
NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid TumoRecruitingI/IIOncologyMerck Sharp & Dohme LLC—90
NCT06723106Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)By InvitationIImmunology & RheumatologyChugai PharmaceuticalMelbourne144
NCT07213674A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic RecruitingIIIOncologyAmgenClayton750
NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor RecruitingIIOncologyMerck Sharp & Dohme LLCParkville322
Page 1 of 25

Sponsor Directory

Sponsors with 2+ trials in Victoria

SponsorTrialsClassTherapeutic AreasPhases
Hoffmann-La Roche325INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Novartis Pharmaceuticals301INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Pfizer259INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Bristol-Myers Squibb245INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
GlaxoSmithKline225INDUSTRY
Renal & UrologyCardiovascularNeurology
I/IINAIII
AbbVie173INDUSTRY
DermatologyCardiovascularNeurology
I/IINAIII
Merck Sharp & Dohme LLC160INDUSTRY
Renal & UrologyCardiovascularNeurology
I/IIIIIIV
Eli Lilly and Company158INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Amgen154INDUSTRY
DermatologyCardiovascularNeurology
I/IINAIII
Boehringer Ingelheim131INDUSTRY
DermatologyRenal & UrologyCardiovascular
NAIIIIV
AstraZeneca126INDUSTRY
CardiovascularNeurologyOncology
NAIIIIV
Gilead Sciences110INDUSTRY
Renal & UrologyCardiovascularOncology
I/IINAIII
Children's Oncology Group109NETWORK
NeurologyOncologyEndocrinology & Metabolism
IIIINA
Bayer107INDUSTRY
Renal & UrologyCardiovascularNeurology
I/IINAIII
Bayside Health105OTHER_GOV
DermatologyCardiovascularNeurology
I/IINAIII
Peter MacCallum Cancer Centre, Australia77OTHER
OncologyOtherMusculoskeletal
I/IINAIII
University of Melbourne73OTHER
CardiovascularNeurologyOncology
I/IINAIII
Sanofi73INDUSTRY
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Murdoch Childrens Research Institute71OTHER
DermatologyCardiovascularNeurology
I/IINAIII
Novo Nordisk A/S64INDUSTRY
Renal & UrologyCardiovascularNeurology
NAIIIIV
Celgene62INDUSTRY
NeurologyOncologyGastroenterology
I/IINAIII
Monash University61OTHER
DermatologyRenal & UrologyCardiovascular
NAIIIIV
Takeda52INDUSTRY
Renal & UrologyCardiovascularNeurology
I/IINAIII
Melbourne Health51OTHER
Renal & UrologyCardiovascularNeurology
I/IINAIII
Genentech, Inc.48INDUSTRY
CardiovascularNeurologyOncology
I/IINAIII
BeiGene47INDUSTRY
OncologyOther
IIIII/II
Janssen Research & Development, LLC47INDUSTRY
CardiovascularNeurologyOncology
NAIIIIV
The Alfred45OTHER
CardiovascularWomen's HealthRespiratory
I/IINAIII
National Cancer Institute (NCI)41NIH
OncologyOtherNeurology
I/IIIIIII/III
Australian and New Zealand Intensive Care Research Centre41OTHER
DermatologyRenal & UrologyCardiovascular
I/IINAIII
Trial Intelligence table shows trials registered 2022–2025 with active/recruiting status. Sponsor directory includes sponsors with 2+ Victorian trials.as of April 2026
Source: ClinicalTrials.gov API v2 · April 2026